Click here to view the Cover Story to this Point/Counter.
The clinical trial design to test neuroprotection has improved dramatically recently, and we now have convincing clinical evidence that neuroprotection can be the next exciting step into the future of glaucoma treatment and early prevention.
With the development of OCT algorithms, we now have the ability to detect damage and progression as much as 2 years before visual field changes occur. We believe the FDA will consider OCT as a surrogate biomarker of visual field progression as the use of (Read more...)
Uncategorized